LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Reporting Period: Quarterly period ended December 31, 1997 (Six months ended December 31, 1997).
Status: Development Stage Company.
Business Overview: BioTime is a biomedical organization engaged in the research and development of synthetic plasma expanders (Hextend, PentaLyte), blood volume substitute solutions, and organ preservation solutions (HetaCool). The company has not yet generated significant operating revenues and relies on equity financing and licensing fees.

Key Financial Metrics

Operating Expenses (Six Months Ended Dec 31, 1997):

• Research and Development: $1,542,548
• General and Administrative: $890,340

Material Changes vs. Prior Period

• Revenue: The company recognized $525,000 in revenue for the three months ended Dec 31, 1997, compared to $0 for the same period in 1996. This revenue stems from license fees and a patent milestone payment under an agreement with Abbott Laboratories.
• Net Loss: Net loss for the three months ended Dec 31, 1997 was $637,177, an improvement from the $754,487 loss in the prior year quarter, despite higher operating expenses.
• Operating Expenses: Research and development expenses increased significantly to $864,276 (three months) and $1,542,548 (six months) compared to $485,659 and $917,825 in the prior year periods, respectively. This increase is attributed to the completion of Phase III clinical trials and preparation of the New Drug Application (NDA).
• Cash Position: Cash and cash equivalents decreased from $7,811,634 at June 30, 1997, to $6,321,242 at December 31, 1997, a reduction of approximately $1.49 million primarily due to operating cash outflows.

Guidance, Outlook, and Risks

Management Commentary and Outlook:

• Product Development: Phase III clinical trials for Hextend are complete. The company initiated the filing of its New Drug Application (NDA) with the FDA on December 17, 1997, and expects to complete submission by March 1998.
• Licensing: An exclusive license agreement with Abbott Laboratories covers the U.S. and Canada. Abbott has agreed to pay up to $40 million in license fees and royalties. As of Dec 31, 1997, $1.4 million had been received, with $687,500 deferred.
• International Expansion: On January 5, 1998, the company signed a letter of intent with Nihon Pharmaceutical Company, Ltd. (subsidiary of Takeda) to negotiate a licensing agreement for Japan.
• Future Funding: Management expects losses to continue for the foreseeable future. Additional financing via equity, debt, or licensing will be required to fund future clinical trials and operations.

Risks and Contingencies:

• Regulatory Approval: Success depends on obtaining FDA and foreign regulatory approvals for Hextend and other products.
• Financing: The company has no significant operating revenues and relies on external capital. Inadequate financing could force the curtailment of operations.
• Clinical Trials: Future clinical trials for new products or new uses of Hextend will require substantial funding and successful outcomes.

Key Facts for Investor Verification

• NDA Submission Timeline: Verify if the New Drug Application for Hextend was successfully submitted to the FDA by the end of March 1998 as projected.
• Abbott Milestone Payments: Monitor the achievement of specific milestones (NDA filing/approval, sales commencement) to trigger the remaining $1.1 million in license fees and future royalties.
• Japan Licensing Deal: Confirm the finalization of the licensing agreement with Nihon Pharmaceutical Company, Ltd. following the January 1998 letter of intent.
• Cash Burn Rate: Assess whether the current cash balance of $6.3 million is sufficient to fund operations until the next anticipated financing event or revenue milestone.
• Stock Split Impact: Note that all share data reflects a 3-for-1 stock split effected on October 30, 1997.